137 related articles for article (PubMed ID: 26605680)
1. Does IV Iron Induce Plasma Oxidative Stress in Critically Ill Patients? A Comparison With Healthy Volunteers.
Lasocki S; Piednoir P; Couffignal C; Rineau E; Dufour G; Lefebvre T; Puy H; Duval X; Driss F; Schilte C
Crit Care Med; 2016 Mar; 44(3):521-30. PubMed ID: 26605680
[TBL] [Abstract][Full Text] [Related]
2. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
[TBL] [Abstract][Full Text] [Related]
3. Effect of intravenous vitamin C on cytokine activation and oxidative stress in end-stage renal disease patients receiving intravenous iron sucrose.
Conner TA; McQuade C; Olp J; Pai AB
Biometals; 2012 Oct; 25(5):961-9. PubMed ID: 22706571
[TBL] [Abstract][Full Text] [Related]
4. The effect of intravenous iron on oxidative stress in hemodialysis patients at various levels of vitamin C.
Eiselt J; Racek J; Opatrný K; Trefil L; Stehlík P
Blood Purif; 2006; 24(5-6):531-7. PubMed ID: 17077626
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized clinical trial of IV iron supplementation for anemia of traumatic critical illness*.
Pieracci FM; Stovall RT; Jaouen B; Rodil M; Cappa A; Burlew CC; Holena DN; Maier R; Berry S; Jurkovich J; Moore EE
Crit Care Med; 2014 Sep; 42(9):2048-57. PubMed ID: 24797376
[TBL] [Abstract][Full Text] [Related]
6. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose.
Pai AB; Conner T; McQuade CR; Olp J; Hicks P
Biometals; 2011 Aug; 24(4):603-13. PubMed ID: 21229380
[TBL] [Abstract][Full Text] [Related]
7. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress.
Swarnalatha G; Ram R; Neela P; Naidu MU; Dakshina Murty KV
Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):852-8. PubMed ID: 20814119
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
[TBL] [Abstract][Full Text] [Related]
9. Iron Use in Critically Ill Patients: No More Stress?
Rakonczay Z
Crit Care Med; 2016 Mar; 44(3):638-9. PubMed ID: 26901550
[No Abstract] [Full Text] [Related]
10. Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients.
Schaller G; Scheiber-Mojdehkar B; Wolzt M; Puttinger H; Mittermayer F; Hörl WH; Födinger M; Sunder-Plassmann G; Vychytil A
Kidney Int; 2005 Dec; 68(6):2814-22. PubMed ID: 16316358
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
[TBL] [Abstract][Full Text] [Related]
12. The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients.
Kumbasar A; Gursu M; Kaya C; Ozturk S; Ergen A; Kemik A; Aydin Z; Uzun S; Karadag S; Kazancioglu R
J Nephrol; 2012; 25(5):825-32. PubMed ID: 22307439
[TBL] [Abstract][Full Text] [Related]
13. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of IV iron compared to oral iron for increment of haemoglobin level in anemic chronic kidney disease patients on erythropoietin therapy.
Adhikary L; Acharya S
JNMA J Nepal Med Assoc; 2011; 51(183):133-6. PubMed ID: 22922860
[TBL] [Abstract][Full Text] [Related]
15. Effect of intravenous iron sucrose on oxidative stress in peritoneal dialysis patients.
Saglam F; Cavdar C; Uysal S; Cavdar Z; Camsari T
Ren Fail; 2007; 29(7):849-54. PubMed ID: 17994454
[TBL] [Abstract][Full Text] [Related]
16. Intravenous iron sucrose reverses anemia-induced cardiac remodeling, prevents myocardial fibrosis, and improves cardiac function by attenuating oxidative/nitrosative stress and inflammation.
Toblli JE; Cao G; Rivas C; Giani JF; Dominici FP
Int J Cardiol; 2016 Jun; 212():84-91. PubMed ID: 27038710
[TBL] [Abstract][Full Text] [Related]
17. Oxidative stress from rapid versus slow intravenous iron replacement in haemodialysis patients.
Tiranathanagul K; Eiam-Ong S; Tosukhowong P; Praditpornsilpa K; Tungsanga K
Nephrology (Carlton); 2004 Aug; 9(4):217-22. PubMed ID: 15363053
[TBL] [Abstract][Full Text] [Related]
18. Effects of carnitine on oxidative stress response to intravenous iron administration to patients with CKD: impact of haptoglobin phenotype.
Armaly Z; Abd El Qader A; Jabbour A; Hassan K; Ramadan R; Bowirrat A; Bisharat B
BMC Nephrol; 2015 Aug; 16():135. PubMed ID: 26268514
[TBL] [Abstract][Full Text] [Related]
19. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo.
Rooyakkers TM; Stroes ES; Kooistra MP; van Faassen EE; Hider RC; Rabelink TJ; Marx JJ
Eur J Clin Invest; 2002 Mar; 32 Suppl 1():9-16. PubMed ID: 11886426
[TBL] [Abstract][Full Text] [Related]
20. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion.
Kooistra MP; Kersting S; Gosriwatana I; Lu S; Nijhoff-Schutte J; Hider RC; Marx JJ
Eur J Clin Invest; 2002 Mar; 32 Suppl 1():36-41. PubMed ID: 11886430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
